# Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer

Source: https://onco.cc/trials/nct05771584/  
OnCo record `nct05771584` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of AST-301 in gastric & gastro-oesophageal junction cancer, run by Aston Sci. Inc., active and no longer recruiting.

## Summary

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer is a phase 2 interventional study registered as NCT05771584 by Aston Sci. Inc., with 24 participants enrolled, started 2023-07-04 and due to reach its primary completion in 2027-02-09. Interventions recorded: AST-301 and rhuGM-CSF.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05771584
- Phase: 2
- Setting: A Phase 2 Study to Evaluate the Safety and Immunological Efficacy of Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Expressing Gastric Cancer (CORNERSTONE-003)
- Sponsor: Aston Sci. Inc.
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT05771584: https://clinicaltrials.gov/study/NCT05771584

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)

---
JSON: https://onco.cc/api/v1/entities/nct05771584.json